Table of contents
In this issue
p329 | doi:10.1038/nrd2312
Editorial: Trials and tribulations
p331 | doi:10.1038/nrd2313
News and Analysis
Cancer vaccines on the horizon | PDF (311 KB)
p333 | doi:10.1038/nrd2325
Where now for new drugs for atherosclerosis? | PDF (311 KB)
p334 | doi:10.1038/nrd2326
News in Brief
Regulatory response to TGN1412 trial disaster announced | Roche deals to enhance diagnostics capabilities | Positive developments for stem-cell therapy | Stats shed light on industry trends | Previous genetic studies of heart disease flawed? | Diabetes combination therapy approved | PDF (559 KB)
p336 | doi:10.1038/nrd2327
Patent watch
Pfizer's Norvasc patent invalidated | Key stem-cell patents rejected | Door opens for generic drug patent challenges | TRPV1 antagonists | PDF (159 KB)
p338 | doi:10.1038/nrd2328
An Audience With
Darren Carroll | PDF (95 KB)
p340 | doi:10.1038/nrd2329
From the analyst's couch
Therapies for Alzheimer's disease | PDF (164 KB)
p341 | doi:10.1038/nrd2314
Fresh from the Pipeline
Lisdexamfetamine dimesylate | PDF (167 KB)
p343 | doi:10.1038/nrd2315
Research Highlights
Anticancer drugs: Mitotic arrest | PDF (118 KB)
p345 | doi:10.1038/nrd2317
Addiction: Cutting down alcohol consumption | PDF (210 KB)
p346 | doi:10.1038/nrd2318
Cancer: To grow and spread | PDF (166 KB)
p346 | doi:10.1038/nrd2320
Infection: New peptide modulator of innate immunity | PDF (125 KB)
p347 | doi:10.1038/nrd2319
Anticancer drugs: Crystal-clear targets? | PDF (203 KB)
p348 | doi:10.1038/nrd2321
In brief
Stem cells | Antibacterial drugs | Nanotechnology | Computational chemistry | PDF (147 KB)
p348 | doi:10.1038/nrd2322
Perspectives
Outlook
Development trends for monoclonal antibody cancer therapeutics
Janice M. Reichert & Viia E. Valge-Archer
p349 | doi:10.1038/nrd2241
Monoclonal antibodies are now established as a key therapeutic modality for a range of diseases, including cancer. Reichert and Valge-Archer overview trends in the development and regulatory approval of anticancer monoclonal antibodies since 1980, with the aim of informing future research and development for this class of therapeutics.
Reviews
The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept
Arpad Szallasi, Daniel N. Cortright, Charles A. Blum & Samer R. Eid
p357 | doi:10.1038/nrd2280
Ten years after the cloning of the capsaicin TRPV1 receptor, TRPV1 antagonists are currently in clinical trials for the treatment of pain. Szallasi and colleagues review the past decade of progress and discuss how TRPV1 antagonists could be beneficial in other disorders.
Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases
Robert A. Casero, Jr & Laurence J. Marton
p373 | doi:10.1038/nrd2243
Endogenous polyamines are essential for cell growth and are known to be dysregulated in cancer and other diseases. Here the potential strategies for modulating polyamine metabolism and function are reviewed with a focus on the use of synthetic polyamine analogues.
Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses
Kate L. Jeffrey, Montserrat Camps, Christian Rommel & Charles R. Mackay
p391 | doi:10.1038/nrd2289
Dual-specificity phosphatases (DUSPs) are a subclass of protein tyrosine phosphatases (PTPs) that interact with and regulate mitogen-activated protein kinases (MAPKs). DUSPs can positively or negatively control immune responses in cancers, infectious diseases and inflammatory diseases, making them promising drug targets for immune-based disorders.
More than one reason to rethink the use of peptides in vaccine design
Anthony W. Purcell, James McCluskey & Jamie Rossjohn
p404 | doi:10.1038/nrd2224
Peptide epitopes represent the minimal immunogenic region of a protein antigen. In the light of new insights into the nature of immunogenic epitopes, and recent advances in peptide delivery, stability and design, Purcell and colleagues review developments in the field of peptide-based vaccines.
